Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study

INTRODUCTION: We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). METHODS: This phase IIb trial comprised a loading dose period to week (W) 4, then maintenance dosing to W52. Patients were randomised 2:1:1:1:2 to subcut...

Descripción completa

Detalles Bibliográficos
Autores principales: Burden, A. David, Bissonnette, Robert, Navarini, Alexander A., Murakami, Masamoto, Morita, Akimichi, Haeufel, Thomas, Ye, Binqi, Baehner, Frank, Terui, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539230/
https://www.ncbi.nlm.nih.gov/pubmed/37731086
http://dx.doi.org/10.1007/s13555-023-01002-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539230/
https://www.ncbi.nlm.nih.gov/pubmed/37731086
http://dx.doi.org/10.1007/s13555-023-01002-1

Ejemplares similares